An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Hodgkin's Lymphoma|NHL (Non-Hodgkin Lymphoma)|Pancreatic Cancer|Breast Cancer|UC (Ureter and Urethera)|Advanced Cancer|Metastatic Cancer
Interventions: DRUG: INCB047986|DRUG: INCB047986|DRUG: Gemcitabine|DRUG: nab-paclitaxel
Sponsor: Incyte Corporation